Biosyngen’s BRG01 Receives FDA Approval for Phase II Clinical Trial

SINGAPORE, Aug. 12, 2024 /PRNewswire/ — Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI…